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Retrotransposons are repetitive DNA sequences that are positioned throughout the
human genome. Retrotransposons are capable of copying themselves and mobilizing
new copies to novel genomic locations in a process called retrotransposition. While
most retrotransposon sequences in the human genome are incomplete and incapable of
mobilization, the LINE-1 retrotransposon, which comprises∼17% of the human genome,
remains active. The disruption of cellular mechanisms that suppress retrotransposon
activity is linked to the generation of aneuploidy, a potential driver of tumor development.
When retrotransposons insert into a novel genomic region, they have the potential
to disrupt the coding sequence of endogenous genes and alter gene expression,
which can lead to deleterious consequences for the organism. Additionally, increased
LINE-1 copy numbers provide more chances for recombination events to occur between
retrotransposons, which can lead to chromosomal breaks and rearrangements. LINE-1
activity is increased in various cancer cell lines and in patient tissues resected from
primary tumors. LINE-1 activity also correlates with increased cancer metastasis. This
review aims to give a brief overview of the connections between LINE-1 retrotransposition
and the loss of genome stability. We will also discuss the mechanisms that repress
retrotransposition in human cells and their links to cancer.
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THE LINE-1 RETROTRANSPOSON IS AN ACTIVE MOBILE
ELEMENT
Retrotransposons, a class of transposable elements (TE), are highly repetitive DNA sequences
positioned throughout the human genome. These structural elements make use of an RNA-
mediated transposition process, allowing them tomove from one location in the genome to another,
while the original copy remains in its original locus. The RNA-based retrotransposons are classified
into the autonomous long terminal repeat (LTR) and the non-LTR containing retrotransposons.
LTR containing retrotransposons, as their name implies, possess LTRs ranging from 100 bp to
over 5 kb in size and are endogenous retroviruses. Long interspersed nuclear elements (LINEs),
comprising 20% of the human genome are a type of non-LTR retrotransposon. Non-autonomous
retrotransposons are a third class of retrotransposons, of which the short interspersed nuclear
elements (SINEs) comprise∼13% of the human genome (Lander et al., 2001).
The human genome contains millions of copies of retrotransposons; however, only a single
non-LTR retrotransposon family, the LINE-1 (L1) family, remains the primary source of
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retrotransposition. The activity of the L1 retrotransposon has
persisted over time within the human genome and its de-
repression is associated with genomic instability and tumor
development (Gasior et al., 2006; Lee et al., 2012). Over 100,000
L1 sequences exist in the human genome; however, most
are rendered inactive by point mutations, rearrangements, or
truncations (Brouha et al., 2003). It was originally estimated that
the average human diploid genome contains ∼80–100 active
L1s that are capable of undergoing retrotransposition (Sassaman
et al., 1997). Of those which are active, six were classified as “hot”
L1s responsible for the bulk of L1 retrotransposition within the
human genome (Brouha et al., 2003). More recently, however,
three independent studies demonstrated that the occurrence of
new L1 insertions is more prevalent than previously thought.
Additionally, a number of the newly inserted “hot” L1s were
found to be extremely polymorphic and specific to a few
individuals, suggesting that L1 retrotransposition may contribute
to the propensity for one individual to develop disease over
another (Beck et al., 2010; Huang et al., 2010; Iskow et al., 2010).
A full-length L1 retrotransposon is∼6 kB in size and contains
a 5′ untranslated region, two non-overlapping open reading
FIGURE 1 | Mobilization of L1 retrotransposons and the cellular mechanisms that inhibit their retrotransposition. A full-length L1 retrotransposon contains
a 5′ untranslated region, two non-overlapping open reading frames (ORF1 and ORF2), and a 3′ untranslated region that ends in a poly (A) tail. ORF1 encodes a
40 kDa RNA-binding protein, whereas ORF2 encodes a 150 kDa protein (ORF2p) with demonstrated endonuclease (EN) and reverse transcriptase (RT) activities.
During a cycle of retrotransposition (gray arrows), L1 is transcribed and exported into the cytoplasm, where translation occurs. ORF1p and ORF2p preferentially bind
to their own mRNA and form ribonucleoprotein (RNP) complexes. The L1 RNP gains access into the nucleus, where the ORF2p endonuclease domain cleaves
genomic DNA to expose a 3′-hydroxyl residue that is used as a primer by the L1 reverse transcriptase to copy the L1 mRNA, a mechanism that has been termed
target-primed reverse transcription (TPRT). The resulting cDNA is then inserted into a novel region in the genome. A number of host cell defense mechanisms exist to
inhibit L1 retrotransposition (black arrows), including L1 DNA methylation, mutation, and/or degradation, L1 RNA degradation, inhibition of L1 RNP formation, and/or
localization to stress granules, and autophagy signaling pathways. All are capable of inhibiting L1 and preventing its mobilization throughout the human genome.
frames (ORF1 and ORF2), and a 3′ untranslated region that
ends in a poly (A) tail (Swergold, 1990; Becker et al., 1993).
ORF1 encodes a 40 kDa RNA-binding protein (Mathias et al.,
1991), whereas ORF2 encodes a 150 kDa protein (ORF2p) with
demonstrated endonuclease and reverse transcriptase activities
(Mathias et al., 1991; Feng et al., 1996; Piskareva et al., 2003).
Interestingly, ORF2p also contains a conserved cysteine-rich
domain recently shown to have a high non-specific affinity
to RNA, which may contribute to the process of reverse
transcription (Piskareva et al., 2013). Various mutants of ORF1p
and ORF2p, have been created and used to demonstrate that
the two proteins are necessary for retrotransposition in a cell
culture based assay (Moran et al., 1996; Wei et al., 2001; Kulpa
and Moran, 2005; Doucet et al., 2010).
The mobility of a L1 retrotransposon is completely dependent
on transcription and translation of its encoded proteins
and therefore incudes both nuclear and cytoplasmic events
essential for retrotransposon duplication (Figure 1). ORF1p
and ORF2p preferentially bind to their own mRNA and form
ribonucleoprotein (RNP) complexes (Leibold et al., 1990; Alisch
et al., 2006; Dmitriev et al., 2007; Doucet et al., 2010). ORF1p
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has been demonstrated to have nucleic acid chaperone activity
that is essential for the retrotransposition process (Martin et al.,
2005, 2008). The L1 RNP gains access into the nucleus, where the
ORF2p endonuclease domain cleaves genomic DNA to expose
a 3′-hydroxyl residue that is used as a primer by the L1 reverse
transcriptase to copy the L1 mRNA, a mechanism that has
been termed target-primed reverse transcription (TPRT). The
resulting cDNA is then inserted into a novel region in the
genome (Cost et al., 2002). A nuclear localization signal has been
identified in ORF2p (Goodier et al., 2004); however, it is unclear
whether the L1 RNP is capable of crossing an intact nuclear
membrane or whether it gains access following nuclear envelope
breakdown (Kubo et al., 2006).
POTENTIAL L1-MEDIATED MECHANISMS
OF TUMOR DEVELOPMENT
Many reports have demonstrated that retrotransposons can
significantly impact the structure of the human genome.
Retrotransposons have adverse effects on genome stability since
multiple copies of the same sequence can hinder precise
chromosomal pairing during mitosis and meiosis, resulting in
DNA double-stranded breaks, more homologous recombination,
chromosome duplication, and increased potential for inefficient
repair of recombination events (Belgnaoui et al., 2006; Farkash
et al., 2006; Gasior et al., 2006). A recent study identified
LINE-LINE-mediated non-allelic homologous recombination
as an important mechanism of structural rearrangement,
contributing to genomic variability and instability (Startek et al.,
2015).
L1 retrotransposition events in the human genome have
been deemed responsible for ∼97 disease-producing insertions
(reviewed in Hancks and Kazazian, 2012). Specifically, direct
insertional mutagenesis caused by L1 retrotransposition
can result in disruption of coding sequence, disruption of
splicing, and/or deregulation of gene expression. Symer and
colleagues identified L1 element inversions, extra nucleotide
insertions, exon deletions, a chromosomal inversion, and
flanking sequence comobilization in the retrotransposon
target site in human tissue culture cells (Symer et al., 2002).
Studies have also shown that L1 acts as more than just an
insertional mutagen, but also that its retrotransposition
activity can result in large genomic deletions (Gilbert et al.,
2002).
L1 retrotransposons exhibit a cis-preference, in which the L1
proteins preferentially use their own L1 RNA as the transcript
for reverse transcription and integration (Wei et al., 2001; Kulpa
and Moran, 2006). However, L1 proteins can also work in
trans to promote mobilization of other RNAs, thus increasing
their potential for causing genomic instability. Non-autonomous
elements including SINEs (Dewannieux et al., 2003) and SVAs
(Raiz et al., 2012), as well as small nuclear RNAs (e.g., U6 snRNA;
Buzdin et al., 2002; Gilbert et al., 2005; Garcia-Perez et al., 2007),
small nucleolar RNAs (e.g., U3 snoRNA; Weber, 2006), and
messenger RNAs (Esnault et al., 2000; Wei et al., 2001) are all
capable of being trans-mobilized via L1. In all of these cases,
retrotransposition of mRNAs results in processed pseudogenes
that bear L1 structural hallmarks. These trans-mobilization
events utilize the ORF1p and/or ORF2p to insert into the human
genome and do not involve sequence specificity. Once these
pseudogenes are inserted back into the genome, they usually lack
introns and promoters, but contain a poly (A) 3′ end and target-
site duplications of varying length (Vanin, 1985; Weiner et al.,
1986; Esnault et al., 2000). Interestingly, siRNAs have been shown
to be expressed from pseudogenes in mouse oocytes, suggesting a
potential way in which theymight influence gene regulation (Tam
et al., 2008). Therefore, generation of processed pseudogenes is a
direct product of endogenous retrotransposition activity in the
human genome that can contribute to genomic diversity and
instability.
Integration of L1 in or near oncogenes or tumor suppressor
genes can contribute to tumor development (Morse et al.,
1988; Miki et al., 1992; Iskow et al., 2010) and progression
of life-threatening cancers, including lung, colon, and breast
cancer in humans (Lee et al., 2012; Criscione et al., 2014). For
example, disruption of the APC gene by a somatic insertion
of L1 was shown to be present in colon cancer and associated
with development of colorectal tumors (Miki et al., 1992). The
APC gene encodes a tumor suppressor involved in maintaining
chromosomal stability during mitosis (Fodde et al., 2001b). In
Apc deficient mouse cells, structural rearrangements, resulting
from chromosomal breakage and recombination are apparent
(Fodde et al., 2001a). Further, cells are defective in chromosome
segregation when they carry a truncated form of Apc (Kaplan
et al., 2001). Other tumor suppressor genes found to be disrupted
by tumor-specific L1 insertions include Mutated in Colorectal
Cancers (MCC) and Suppression of Tumorigenicity 18 (ST18;
Shukla et al., 2013). Furthermore, since L1 machinery acts to
trans-mobilize other RNAs, those insertions can also impact
expression of genes. Alu, a type of SINE present in higher copy
numbers than L1, can be trans-mobilized, leading to cancer-
associated gene insertions. Sites ofAlu insertions include the APC
locus and this was associated with Desmoids tumors (Halling
et al., 1999), the tumor suppressor NF-1 (neurofibromatosis
type I; Wallace et al., 1991), and the BRCA1 and BRCA2
breast/ovarian cancer related genes (Miki et al., 1996; Teugels
et al., 2005). SVA elements can also be mobilized by the L1
retrotransposition machinery, leading to disease (Ostertag et al.,
2003). In one study, mobilization of SVA resulted in deletion
of the HLA-A gene in three Japanese families; a number of
individuals in these families were aﬄicted with leukemia (Takasu
et al., 2007).
Telomerase reactivation, as a means to maintain telomeres,
occurs in the early stages of carcinogenesis to promote cancer
cell immortalization (Counter et al., 1992; Kim et al., 1994).
Transcriptional regulation of hTERT, the catalytic subunit of
telomerase, is a major mechanism for telomerase activation in the
cancer setting. In a recent study, L1 was shown to contribute to
tumor pathogenicity by inducing hTERT and helping to maintain
telomeres in telomerase-positive tumor cells. Depletion of L1
resulted in reduced telomere length, suggesting that L1 is a
reasonable target in the treatment of telomerase-positive cancer
(Aschacher et al., 2015).
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L1 EXPRESSION IN CANCERS
Given that L1 retrotransposition can lead to genomic instability
and genetic heterogeneity is a common feature in tumor
initiating cells, it is not surprising that expression of the L1-
encoded ORF1p is reported to be a hallmark of many human
cancers, with almost half (47%) of the human neoplasms
examined being immunoreactive for L1 (Rodic et al., 2014).
L1 positive neoplasms included invasive breast carcinomas
(97% L1 positive), high-grade ovarian carcinomas (91.5% L1
positive), and pancreatic ductal adenocarcinomas (PDACs; 89%
L1 positive). Carcinomas originating in the endometrium, biliary
tract, esophagus, bladder, head and neck, lung, and colon were
also frequently L1 immunoreactive (22.6–76.7% L1 positive;
Rodic et al., 2014). In a separate study, increased ORF1p
expression and novel L1 insertions in PDAC were observed in
matched primary and metastatic tissues. However, the overall
results showed discordant rates of retrotransposition, suggesting
that while increased L1 retrotransposition may not be a direct
cause ofmetastatic PDAC, it may contribute to gene disregulation
leading to metastasis (Rodic et al., 2015). Furthermore, activation
of L1 increases the risk of epithelial-mesenchymal transition
and metastasis in epithelial cancer (reviewed in Rangasamy
et al., 2015) and promotes proliferation and invasion of LoVo
colorectal cancer cells (Li et al., 2014) and MDA-MB-231 breast
cancer cells (Yang et al., 2013). ORF1p and ORF2p levels
are upregulated in breast cancers compared to normal tissues.
Cytoplasmic levels of ORF1p and ORF2p are elevated in DCIS
breast cancers compared to highly invasive cancers. Conversely,
nuclear levels of ORF1p and ORF2p were found to be higher in
invasive breast cancers and correlated with increased lymph node
metastasis and poor patient survival (Harris et al., 2010; Chen
et al., 2012). Furthermore, inhibition of the L1-encoded reverse
transcriptase in breast cancer cells was demonstrated to reduce
the rate of proliferation and promote cellular differentiation
(Patnala et al., 2014). Finally, L1 activity and expression was
elevated in rat chloroleukemia cells, suggesting that mobilization
of this retrotransposon may contribute to the genomic instability
observed in this model of blood cancer (Kirilyuk et al., 2008).
Hypomethylation of L1 DNA has been observed in various
cancers and is associated with an increase in transcriptional
activation and expression of L1 (Alves et al., 1996; Asch
et al., 1996; Kitkumthorn et al., 2012; Murata et al., 2013;
Criscione et al., 2014; Park et al., 2014). L1 hypomethylation
can occur early in tumorigenesis and is associated with bladder
(Patchsung et al., 2012; Salas et al., 2014), gastric (Shigaki et al.,
2013; Baba et al., 2014a), colon (Ogino et al., 2008; Antelo
et al., 2012; Murata et al., 2013), lung (Saito et al., 2010),
and breast cancers (Park et al., 2014). L1 hypomethylation is
associated with poor prognosis of lung adenocarcinoma (Ikeda
et al., 2013), hepatocellular carcinoma via activation of c-Met
(Zhu et al., 2014), esophageal squamous cell carcinoma (ESCC;
Iwagami et al., 2013), and with inferior survival in colorectal
carcinomas with high microsatellite instability (Inamura et al.,
2014). Additionally, L1 hypomethylation in ESCC was shown to
be significantly associated with lymph nodemetastasis, frequency
of p53 mutation, and chromosomal instability (Kawano et al.,
2014). In a separate study, L1 hypomethylation in ESCC patient
samples was associated with an increase in CDK6 expression
(Baba et al., 2014b). This may contribute to the aggressiveness
of tumors since CDK6 is known to promote tumor progression
by stimulating proliferation and angiogenesis (Kollmann et al.,
2013). Finally, hypomethylation of L1 in colorectal cancer can
lead to activation of oncogenes important inmetastasis, including
MET, RAB1P, and CHRM3 (Hur et al., 2014). It was observed that
specific L1 sequences residing within the intronic regions of these
proto-oncogenes were hypomethylated and reduced methylation
of specific L1 elements within the MET gene correlated with an
induction of MET expression (Hur et al., 2014). However, since
methylation levels of repetitive L1 elements often tightly correlate
with global DNA methylation levels, it is difficult to conclude
that L1 hypomethylation directly results in the increased genomic
instability found in tumors.
MECHANISMS THAT INHIBIT L1
RETROTRANSPOSITION ARE OFTEN
DEREGULATED IN CANCER
As the uncontrolled movement of retrotransposons throughout
the genome can have deleterious consequences for genome
stability and health in general, a number of defense mechanisms
exist in human cells to repress their movement. These
mechanisms exist at the DNA, RNA, and protein levels to inhibit
L1 and retrotransposition (Figure 1).
DNA methylation status is a major determinant of gene
expression changes within the human genome and is involved in
various biological processes including cancer (Liu et al., 2003).
As discussed above, hypomethylation of L1 DNA is associated
with an increase in L1 expression. Conversely, methylation of
L1 within the CpG rich 5′-UTR represses its ability to be
activated and transcribed, thereby minimizing the exposure
of genomic DNA to L1-associated damage (Hata and Sakaki,
1997; Weisenberger et al., 2005; Barchitta et al., 2014). DNA
methylation, therefore, is a key mechanism for L1 silencing. It
has been shown in mouse embryonic stem cells that methylation
of the L1 promoter is maintained by DNA methylatransferases,
including Dmnt1 and Dmnt3a and/or -3b (Woodcock et al.,
1998; Liang et al., 2002).
Other epigenetic mechanisms have been reported to be
involved in regulating L1 expression. One study showed that
reporter genes introduced into human embryonic carcinoma-
derived cell lines by engineered L1 retrotransposons were
rapidly silenced during or shortly after their integration
(Garcia-Perez et al., 2010). Treatment of the cells with
histone deacetylase inhibitors reversed the silencing and ChIP
experiments demonstrated that a change in the chromatin
status at the L1 integration site correlated with reactivation
of the reporter gene (Garcia-Perez et al., 2010). Other
studies involving chromatin structure averaged global histone
modifications and found that histone H3 lysine nine methylation
is enriched at human retrotransposons, suggesting that histone
methylation may play a role in repressing recombination of
these retrotransposons (Kondo and Issa, 2003; Martens et al.,
2005; Goodier and Kazazian, 2008). Low levels of the silencing
histone modification H3K27me3 at L1 loci in conjunction with
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L1 hypomethylation has been shown to support an active
role in rectal cancer prognosis and a poor clinical outcome
(Benard et al., 2013). Conversely, high levels of the activating
histone modification H3K9Ac at L1 loci were associated with
poor patient survival. This indicates that L1 methylation and
histone modifications work closely together in determining gene
expression and tumor progression (Benard et al., 2013).
Global chromatin organization is also involved in repression
of Drosophila melanogaster retrotransposons. Studies in the fly
have identified a role for the chromatin organizing complex,
Condensin II in repressing retrotransposition in somatic cells and
tissues. The Condensin II subunit, dCAP-D3, promotes silencing
of retrotransposon-containing loci by maintaining boundaries
of repressive histone modifications to repress retrotransposon
transcription and ultimately inhibit retrotransposition (Schuster
et al., 2013). Furthermore, decreased dCAP-D3 expression
impacts chromatin structure, resulting in DNA double strand
breaks within the retrotransposon sequence, an increase in
homologous pairing, and an increase in global retrotransposon
copy number. While global chromatin regulators have yet to be
implemented in L1 repression, CAP-D3, and Condensin II are
conserved and further studies are necessary to determine whether
they also inhibit retrotransposition in human cells.
Epigenetic modification, however, is not the only mechanism
employed by cells to inhibit retrotransposition. Exciting new
evidence from multiple labs suggests that a host of cellular
proteins employ distinct mechanisms to accomplish the
inhibition.
One mechanism includes targeting the L1 RNA intermediate
to prohibit insertion of L1 into the human genome. The
ribonucleoprotein hnRNPL, which plays multiple roles in RNA
metabolism, has been shown to directly interact with L1 RNA
to negatively regulate retrotransposition. hnRNPL does so by
decreasing the steady-state levels of the L1 RNA (Peddigari
et al., 2013). Downregulation of L1 mRNA and subsequently,
reduced expression of the ORF1p and ORF2p by RNase L was
also shown to restrict L1 mobilization; whereas, siRNA-mediated
knockdown of endogenous RNase L lead to a significant increase
in L1 retrotransposition events in a human ovarian cancer cell
line (Zhang et al., 2014). Similarly, the melatonin receptor 1
(MT1) inhibits retrotransposition through downregulation of
L1 mRNA and ORF1p. Researchers showed that antagonists
directed against MT1 abolished this effect in a dose-dependent
manner (deHaro et al., 2014). Furthermore, melatonin-rich blood
suppressed endogenous L1 RNA during in situ perfusion of
tissue-isolated xenografts of human pancreatic cancer (deHaro
et al., 2014).
Innate immune defenses can also inhibit retrotransposition of
L1. Guo and colleagues demonstrated that autophagy degrades
the L1 RNA intermediate, preventing new insertions into
the genome and promoting genome stability. Degradation
of retrotransposon RNA was facilitated by receptors
involved in activating autophagy signaling pathways, NDP52
and p62. Interestingly, this study also showed that mice
lacking Atg6/Beclin1, a gene critical for the formation of
autophagosomes, accumulate retrotransposon RNA and new
genomic insertions of L1 (Guo et al., 2014).
L1 RNP formation and safe delivery of the RNP to genomic
DNA is essential for TPRT to occur; therefore, targeting the
RNP for degradation is a useful mechanism to inhibit this
process. The RNA helicase, MOV10 directly associates with
the L1 RNP (Goodier et al., 2012) and similar to SAMHD1
(Zhao et al., 2013) inhibits L1 retrotransposition by promoting
stress granule formation (Arjan-Odedra et al., 2012; Li et al.,
2013); stress granules are ribonucleoprotein cytosolic foci that
appear under cellular stress and often act to promote mRNA
degradation (Kedersha et al., 2005). Further, the L1 ORF1p was
shown in a separate study to localize in stress granules with
components of RISC, suggesting a mechanism for controlling
retrotransposition and the associated genomic damage (Goodier
et al., 2007). More recently, the zinc-finger antiviral protein,
ZAP was shown to inhibit L1 retrotransposition by binding to
the L1 RNP and inhibiting accumulation of L1 RNA (Goodier
et al., 2015; Moldovan and Moran, 2015). ZAP colocalizes with
the RNP in cytoplasmic stress granules and interacts with a
number of novel proteins, including MOV10 (Goodier et al.,
2015; Moldovan and Moran, 2015).
Another mechanism to inhibit retrotransposition involves
targeting the single-strand DNA that arises during the process of
L1 integration, to repress its mobilization. These cellular proteins
can directly promote degradation of L1, thereby inhibiting
retrotransposition. For example, the APOBEC3 (A3) family of
cytidine deaminases functions to inhibit L1 retrotransposition
by deaminating the transiently exposed cDNA, creating C-to-
U conversions (Richardson et al., 2014). This may then target
the mutated retrotransposon DNA for degradation through
endonuclease activity. Additionally, the endonucleases TREX1
(Stetson et al., 2008) and ERCC1/XPF (Gasior et al., 2008) can
physically cleave the reverse-transcribed cDNA of L1, thereby
inhibiting retrotransposition.
CONCLUSIONS
Undeniably, L1 retrotransposons are an interesting and
important component of the human genome. The activity of L1
retrotransposons can generate a wide array of genomicmutations
and rearrangements, with potentially serious consequences for
the stability of the genome. L1s are frequently hypomethylated
and expressed in human cancers and their increased activity
correlates with tumor progression and metastasis. Additionally,
L1-insertion-mediated interference with normal RNA processing
and expression also contributes to cancer development. Further
studies on L1 retrotransposition, their effects on local and
global genome organization, and the identification of novel
mechanisms which repress retrotransposition to prevent tumor
development will broaden our understanding of the impact of
retrotransposons on genetic diversity and human health.
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